Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX®) for cervical dystonia

Allison Brashear, Patrick Hogan, Maureen Wooten-Watts, Albert Marchetti, Raf Magar, John Martin

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalAdvances in Therapy
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Torticollis
Type A Botulinum Toxins
Observation
Therapeutics
Medical Records

Keywords

  • Botulinum toxin type A
  • Cervical dystonia
  • Spasmodic torticollis

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX®) for cervical dystonia. / Brashear, Allison; Hogan, Patrick; Wooten-Watts, Maureen; Marchetti, Albert; Magar, Raf; Martin, John.

In: Advances in Therapy, Vol. 22, No. 1, 01.01.2005, p. 49-55.

Research output: Contribution to journalReview article

Brashear, Allison ; Hogan, Patrick ; Wooten-Watts, Maureen ; Marchetti, Albert ; Magar, Raf ; Martin, John. / Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX®) for cervical dystonia. In: Advances in Therapy. 2005 ; Vol. 22, No. 1. pp. 49-55.
@article{c923bbcd1cf640b48771abf4588ce59f,
title = "Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX{\circledR}) for cervical dystonia",
abstract = "Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.",
keywords = "Botulinum toxin type A, Cervical dystonia, Spasmodic torticollis",
author = "Allison Brashear and Patrick Hogan and Maureen Wooten-Watts and Albert Marchetti and Raf Magar and John Martin",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/BF02850184",
language = "English (US)",
volume = "22",
pages = "49--55",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "1",

}

TY - JOUR

T1 - Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX®) for cervical dystonia

AU - Brashear, Allison

AU - Hogan, Patrick

AU - Wooten-Watts, Maureen

AU - Marchetti, Albert

AU - Magar, Raf

AU - Martin, John

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.

AB - Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.

KW - Botulinum toxin type A

KW - Cervical dystonia

KW - Spasmodic torticollis

UR - http://www.scopus.com/inward/record.url?scp=18444418557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444418557&partnerID=8YFLogxK

U2 - 10.1007/BF02850184

DO - 10.1007/BF02850184

M3 - Review article

C2 - 15943222

AN - SCOPUS:18444418557

VL - 22

SP - 49

EP - 55

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 1

ER -